THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Biogen cuts deal to refill drug lineup

Biotech to pay Calif. firm for rights to help develop MS treatment, 2 others

By Jeffrey Krasner
Globe Staff / August 3, 2005

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Making good on a promise to use a war chest of cash to replenish its drug pipeline, Biogen Idec Inc. of Cambridge yesterday said it was licensing three promising drug candidates from Protein Design Labs Inc. (Full article: 569 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass